Document Type

Journal Article

Publication Date

2018

Journal

Frontiers in Immunology

Volume

9

Inclusive Pages

556

DOI

10.3389/fimmu.2018.00556

Abstract

Patients with primary immunodeficiency disorders (PID) have an increased risk from acute and chronic Epstein-Barr Virus (EBV) viral infections and EBV-associated malignancies. Hematopoietic stem cell transplantation (HSCT) is a curative strategy for many patients with PID, but EBV-related complications are common in the immediate post-transplant period due to delayed reconstitution of T cell immunity. Adoptive T cell therapy with EBV-specific T cells is a promising therapeutic strategy for patients with PID both before and after HSCT. Here we review the methods used to manufacture EBV-specific T cells, the clinical outcomes, and the ongoing challenges for future development of the strategy. © 2018 McLaughlin, Bollard and Keller.

Comments

Reproduced with permission of Frontiers Media SA. Frontiers in Immunology

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Peer Reviewed

1

Open Access

1

Share

COinS